[Prognostic significance of epidermal growth factor receptors in stage I-II breast cancer: results of a six-year follow-up].

The disease-free (DFS) and overall (OS) survival was retrospectively assessed using mono- and multiparametrical methods in 197 patients with T1-2N0-1M0 tumors of the breast during a 3-73 month follow-up. No significant differences in DFS or OS were observed between epidermal growth factor receptor(EGFR)-positive or negative patients, either in the general study group or in those without metastases in the lymph nodes. However, DFS was much and significantly higher in patients with an "endocrine" receptor phenotype of tumor (EGFR-ER+PR+) than with an "auto/paracrine" one (EGFR+ER-PR).